As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...

Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...

Mizuho analyst Graig Suvannavejh downgraded Intra-Cellular (ITCI) to Neutral from Outperform with a price target of $132, down from $140, ...

As of 20 February 2025, the index has steadily increased, rising 14.41% in the last 12 months and 4.21% year to date in 2025.

The final trades of the day with the Fast Money traders.

Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...

Sanctuary Advisors LLC cut its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 10.4% during the fourth quarter, ...

Teva (TEVA) stock and Alvotech (ALVO) stock in focus as duo launches Selarsdi, a biosimilar to J&J's (JNJ) Stelara after a ...

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

Empire Life Investments Inc. decreased its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 7.6% in the 4th quarter, ...